CONMED Corporation reported their Q4 2020 financial results, highlighting the resilience of their team in a challenging operating environment due to the ongoing impacts of COVID-19 on surgical procedure volumes.
CONMED faced challenges in Q4 2020 due to the impact of COVID-19 on surgical procedure volumes.
The company expects improvement in procedure volumes as vaccines become more readily available in 2021.
CONMED anticipates full-year 2021 revenue between $975 million and $1.02 billion.
The company forecasts full-year 2021 adjusted diluted net earnings per share in the range of $2.85 to $3.05.
The Company expects full-year 2021 revenue between $975 million and $1.02 billion and forecasts full-year 2021 adjusted diluted net earnings per share in the range of $2.85 to $3.05.